← Eichor
Study identifier: NCT06352632 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

ACT-GLOBAL Adaptive Platform Trial for Stroke

Condition: Stroke  ·  Sponsor: The George Institute

PhasePhase 3
Planned participants20000
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Stroke is causing 6.6 million deaths and is a major cause of disability worldwide in 2019. There remains an urgent need for interventions that improve outcomes which can be implemented with wide applicability for stroke. ACT-GLOBAL is a multi-factorial, multi-arm, multi-stage, randomised, global adaptive platform trial for stroke, aiming to identify the treatment/s associated with the highest chance of improving outcome in stroke patients. In ACT-GLOBAL multiple questions will be evaluated simultaneously and sequentially as data accrues and can evaluate interactions between different treatment options.

This description comes directly from the study's public registry record.

Talk to the study team

Xiaoying Chen, PhD  ·  +61280524549  ·  xchen@georgeinstitute.org.au

Bijoy Menon, MD, PhD  ·  +14033381198  ·  docbijoymenon@gmail.com

Always discuss trial participation with your own doctor first.

Locations (2)

The George Institute for Global HealthSydney, New South Wales, AustraliaRecruiting
University of CalgaryCalgary, Alberta, CanadaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06352632